129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease
Kern,A. L.,Voskrebenzev,A.,Klimes,F.,Pink,I.,Schupp,J. C.,Seeliger,B.,Konietzke,M.,Peter,D.,Risse,F.,Welte,T.,Wacker,F.,Hohlfeld,J. M.,Shin,H.-O.,Prasse,A.,Vogel-Claussen,J.
DOI: https://doi.org/10.1183/13993003.congress-2024.oa5465
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Introduction: Novel antifibrotic therapy slows down lung function decline in patients with progressive fibrosing ILD (PF-ILD). While traditional lung function measures like FVC have limited sensitivity for early lung function alterations, more sensitive biomarkers for assessment of fibrosis progression and efficacy of new treatments are desirable. Aims and Objectives: The aim was to investigate the potential of hyperpolarized 129 Xe MR imaging markers for noninvasive assessment of disease progression in patients on antifibrotic therapy in an observational clinical trial. Methods: 14 PF-ILD patients underwent 129 Xe MRI and lung function testing at baseline and 3 and 6 months post initiation of clinically indicated antifibrotic therapy. MRI included dissolved-phase spectroscopy with frequency-selective excitation increasing signal from red blood cells (RBC) relative to membrane (M) to obtain averaged RBC:M and chemical shift saturation recovery (CSSR) quantifying dynamic 129 Xe uptake. CSSR data were analysed using MOXE to obtain surface-volume ratios (S/V). Results: Mean RBC:M was reduced at 6 months (P=0.01, –11%) and 3 months (P=0.04, –9%) vs. baseline. S/V was reduced at 6 months (P=0.007, –16%), but not 3 months (P=0.09, –13%). D LCO (mmol/min/kPa) was reduced at 6 (P=0.01, –10%), but not 3 months (P=0.76, –2%). FVC (L) did not change (6 months: P=0.81, –2%, 3 months: P=0.22, +2%). Conclusions: RBC:M seems more sensitive to early changes of alveolar membrane function than D LCO and FVC. S/V reduction is reflective of declining functional alveolar surface. RBC:M and S/V may be useful for monitoring PF-ILD patients on antifibrotic therapy.
respiratory system